Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddy's drops 4...

    Dr Reddy's drops 4 percent as Duvvada facility receives EIR

    Written by Ruby Khatun Khatun Published On 4 Jan 2018 5:38 AM  |  Updated On 4 Jan 2018 5:38 AM
    Dr Reddys drops 4 percent as Duvvada facility receives EIR

    New Delhi: Shares of Dr Reddy's Laboratories fell over 4 percent in Wednesday's trade amid reports that an establishment inspection report (EIR) has been issued to the company's Duvvada facility, citing some issues.


    Following the report, the stock fell 4.5 percent to hit a low of Rs 2,299 on BSE. The exchange has sought clarification from the drug maker regarding the news. The reply is awaited.


    On the BSE, 57,000 shares were traded on the counter so far compared with average daily volumes of 40,000 shares in the two weeks.


    The media report suggested that that Duvvada facility status continues to be classified as the official action initiated (OAI), which suggests regulatory or admin sanctions by the drug regulator have been initiated.


    The drug maker reported 1.1 per cent YoY drop in consolidated net profit at Rs 305.40 crore in the September quarter, on 1.1 percent YoY decline in consolidated net sales at Rs 3,546 crore.

    Dr ReddyDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsdropsDuvvada facilityEIREstablishment Inspection Reportindian pharma newsofficial action initiatedpharma newspharma news indiareceives
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok